We have reported that
hepatitis B X-interacting
protein (HBXIP, also termed LAMTOR5) can act as an oncogenic transcriptional co-activator to modulate gene expression, promoting
breast cancer development.
Pyruvate kinase muscle isozyme M2 (PKM2), encoded by PKM gene, has emerged as a key
oncoprotein in
breast cancer. Yet, the regulatory mechanism of PKM2 is still unexplored. Here, we report that HBXIP can upregulate PKM2 to accelerate proliferation of
estrogen receptor positive (ER+)
breast cancer. Immunohistochemistry analysis using
breast cancer tissue microarray uncovered a positive association between the expression of HBXIP and PKM2. We also discovered that PKM2 expression was positively related with HBXIP expression in clinical
breast cancer patients by real-time PCR assay. Interestingly, in ER+
breast cancer cells, HBXIP was capable of upregulating PKM2 expression at
mRNA and
protein levels in a dose-dependent manner, as well as increasing the activity of PKM promoter. Mechanistically, HBXIP could stimulate PKM promoter through binding to the -779/-579 promoter region involving co-activation of
E2F transcription factor 1 (E2F1). In function, cell viability, EdU, colony formation, and xenograft
tumor growth assays showed that HBXIP contributed to accelerating cell proliferation through PKM2 in ER+
breast cancer. Collectively, we conclude that HBXIP induces PKM2 through
transcription factor E2F1 to facilitate ER+
breast cancer cell proliferation. We provide new evidence for the mechanism of transcription regulation of PKM2 in promotion of
breast cancer progression.